Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Epipodophyllotoxin (-)-epipodophyllotoxin) is a natural product derived from plants in the family Epipodophyllotoxin, belonging to the lignan class of compounds. As a natural product with significant biological activity, epipodophylloxin has attracted widespread attention in the field of antitumor drug development. Its derivatives, such as etoposide and teniposide, have been successfully applied in the treatment of various malignant tumors, demonstrating the important role of these compounds in anticancer drug development. In recent years, with advances in molecular biology and pharmacological techniques, the mechanism of action of epiglidaltoxin, its molecular targets, and druggable characteristics have been deeply explored, providing a theoretical foundation for its clinical application.
This paper systematically reviews the chemical structure and physicochemical properties of epiphysular toxin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and looks ahead to its clinical application prospects in anti-tumor therapy, aiming to provide comprehensive reference materials for researchers in the field of natural product pharmacology.
The chemical name of epipodophyllotoxin is (-)-Epipodophyllotoxin, CAS number 4375-07-9, molecular formula C22H22O8, and molecular weight 414.41. Its structure belongs to the lignan class, with a core framework of a tetracyclic structure containing multiple hydroxyl and methoxy substituents, giving it unique chemical properties. The structural characteristics of epipophylloxin determine its ability to bind to various biomacromolecules, especially showing significant activity in inhibiting DNA topoisomerase.
In terms of physicochemical properties, the LogP value of the epipophyllal toxin is 1.947, indicating moderate lipid solubility that facilitates cell membrane penetration; TPSA (Topological Polar Surface Area) is 92.68 Ų, reflecting moderate molecular polarity and favorable interactions with biological targets. Low water solubility (0.12 mg/mL) suggests limited solubility in the aqueous phase, which may affect its bioavailability. The blood-brain barrier penetration capability is relatively high, indicating its potential application value in the treatment of central nervous system diseases. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity; The Ames test result was 0.0, indicating a low genotoxicity risk and meeting safety requirements.
Epiphyllum toxin is mainly found in plants of the Podophyllum family, especially species of the genus Podophyllum, such as Podophyllum peltatum and Podophyllum hexandrum. These plants are used in traditional medicine to treat various diseases, especially tumors and viral infections.
Traditional methods for extracting epiphylloxin include solvent extraction, column chromatography separation, and crystallization purification. Generally, ethanol or methanol is used as the extraction solvent, and crude extracts are obtained by reflux extraction, followed by separation and purification by silica gel column chromatography or high-performance liquid chromatography (HPLC). In recent years, the application of emerging technologies such as ultrasound-assisted extraction and microwave-assisted extraction has improved extraction efficiency and purity, while reducing solvent usage and environmental pollution.
Moreover, research on biosynthetic pathways provides a theoretical basis for the biosynthesis regulation of epipophylloxin, and the application of genetic engineering and metabolic engineering technologies is expected to achieve efficient biosynthesis, addressing the challenges of wild resource scarcity and environmental protection.
Epipodophylloxin and its derivatives demonstrate broad pharmacological activity in the field of antitumor treatment. Its main antitumor mechanisms include inhibiting DNA topoisomerase II (TOP2A) activity, inducing DNA double-strand breaks, blocking the tumor cell cycle progression, and promoting apoptosis. In addition, epigdophylloxin can regulate various signaling pathways, affecting cell proliferation, migration, and invasion capabilities.
In vitro experiments show that epipodophylloxin has significant cytotoxic effects on various tumor cell lines, including lung cancer, breast cancer, colorectal cancer, and leukemia. Animal model studies further confirmed its anti-tumor effects, manifested as tumor growth inhibition and reduced metastasis.
In addition to its antitumor activity, epiopophylloxin also exhibits various pharmacological effects such as anti-inflammatory and antiviral effects, but related research is still in its early stages and requires further in-depth exploration.
The antitumor effect of epipophyllal toxin is mainly achieved through multi-target coordinated regulation. Key targets include:
In summary, epipophylloxin achieves comprehensive regulation of tumor cells through the synergistic action of multiple targets and multiple pathways, enhancing its anti-tumor effect.
The druggability parameters of epipodophylloxin indicate that it has promising potential for drug development. The molecular weight of 414.41 and LogP of 1.947 comply with the Lipinski rule, suggesting good oral bioavailability potential. TPSA of 92.68 Ų is moderate, which facilitates cell membrane penetration and target binding. Low water solubility is a major challenge in formulation development, requiring improvements in solubility and stability through salt formation and nanocarrier technologies.
The high penetration ability of the blood-brain barrier suggests its potential advantages in treating central nervous system tumors and related diseases. hERG is inhibitively negative and Ames tests show no mutagenicity, indicating good safety and low risks of cardiotoxicity and genotoxicity.
Pharmacokinetic studies show that epipophylloxin is widely distributed in the body, with metabolism mainly via hepatic enzyme systems, and excretion primarily through bile and urine. Its plasma half-life is moderate, supporting the design of clinical dosing regimens. Due to its poor water solubility and limited bioavailability, it is necessary to optimize the route of administration and formulation to enhance therapeutic efficacy.
Epipophyltoxin and its derivatives have become lead compounds in various antitumor drugs, with clinical applications mainly focused on chemotherapy regimens relying on toposide and tipoposide to treat lung cancer, lymphoma, small cell lung cancer, and other malignant tumors. In the future, with deeper understanding of the mechanisms of epipophyllal toxin and advances in drug design technology, it is expected that more efficient and low-toxicity novel anti-tumor drugs will be developed.
In addition, the multi-target action characteristics of epipophylloxin provide a theoretical basis for combination drug strategies, allowing for synergistic use with other targeted drugs and immunotherapy drugs to enhance tumor treatment outcomes. Its excellent blood-brain barrier penetration also opens new possibilities for treating brain tumors and neurological diseases.
In formulation development, the application of nanotechnology, liposomal carriers, and sustained-release formulations will effectively address the issues of poor water solubility and low bioavailability, promoting clinical translation. Future research should focus on optimizing drug design, clarifying pharmacokinetic profiles, evaluating long-term safety, and exploring new indications.
As a natural product with significant clinical value, epigmodal toxin has a unique chemical structure and multi-target anti-tumor mechanism, making it an important template for anticancer drug development. Despite challenges in water solubility and bioavailability, its good safety and blood-brain barrier penetration offer broad prospects for clinical application.
In the future, through multidisciplinary integration combined with modern medicinal chemistry, molecular biology, and drug delivery technologies, it is expected to further tap the potential of epignophylloxin and promote its broader clinical application to benefit a wide range of patients. Ongoing research in the field of natural product pharmacology will provide a solid foundation for the innovative drug development of epiophylloxin and its derivatives.
